Diabetes, hypertension, and cardiovascular disease an update

Hypertension

Volumn 37, Issue 4, 2001, Pages 1053-1059

  Sowers, James R ^a,b,c,d,e   Epstein, Murray ^a,b,c   Frohlich, Edward D ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SUNY HSC   (United States)

^e Box 1205 ^*  (United States)

Author keywords

Blood pressure; Cardiovascular diseases; Diabetes; Hypertension, essential

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; THIAZIDE DIURETIC AGENT;

ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERTENSION; MICROALBUMINURIA; MORBIDITY; MORTALITY; OBESITY; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOCYTE AGGREGATION;

EID: 0035050460     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.37.4.1053     Document Type: Review

References (60)

1. National high blood pressure education program working group report on hypertension in diabetes
2. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: An update
3. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study
4. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated hypertension
5. Long-term effects on plasma lipids of diet and drugs to treat hypertension: Treatment of Mild Hypertension Study (TOMHS) Research Group
6. The outcome of STOP-Hypertension-2 in relation to the 1999 WHO/ISH hypertension guidelines
7. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
8. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators
9. Antihypertensive therapy and the risk of type 2 diabetes mellitus
10. Effects of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
11. Effects of calcium channel blockers in older patients with diabetes and systolic hypertension
12. UK Prospective Diabetes Study 38: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes
13. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
14. Risk factors for arterial disease in diabetes: Hypertension
15. Hyperinsulinemic microalbuminuria: A new risk indicator for coronary heart disease
16. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: A systematic overview of the literature
17. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
18. Comorbidity of hypertension and diabetes: The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET)
19. Clinical advisory treatment of hypertension in diabetes
20. Effects of ramipril on cardiovascular and microvascular outcomes in peoples with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
21. ACE inhibition but not angiotensin II antagonism reduced fibrinogen and insulin resistance in overweight hypertensive patients
22. Insulin resistance in adipocytes from spontaneously hypertensive rats: Effect of long-term treatment with enalapril and losartan
23. Angiotensin II inhibits insulin signaling in aortic smooth muscle cell at multiple levels
24. Cross-talk between insulin and angiotensin signaling systems
25. Angiotensin II induces insulin resistance independent of changes in interstitial insulin
26. Temporal activation of p70 S6 kinase and Akt1 by insulin: PI3-kinase-dependent and -independent mechanisms
27. +-ATP pump stimulation by IGF-1 in VSMC
28. Imadapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat
29. Potentiating of bradykinin action by ACE inhibitors
30. ACE inhibition and glucose transport in insulin resistant muscle: Roles of bradykinin and nitric oxide
31. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without myocardial infarction
32. Diabetes mellitus and cardiovascular disease in women
33. Morbidity and mortality in diabetes in the Framingham population: Sixteen-year follow-up study
34. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
35. Uric acid: A risk factor for coronary artery disease
36. Influence of sex, diabetes and ethanol on intrinsic contractile performance of isolated rat myocardium
37. Troglitazone attenuates high glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes
38. Reduced contractile response to insulin and IGF-1 in ventricular myocytes from genetically obese Zucker rats
39. 2+ currents in ventricular myocytes from rats with chronic diabetes
40. + currents depends on the integrity of the cytoskeleton
41. Effects of diabetic cardiomyopathy on regional electrophysiologic characteristics of rat ventricle
42. + ATPase activities and gene expression in alloxan-induced diabetes in rats
43. Mechanisms that may be involved in calcium tolerance of the diabetic heart
44. Differential gene expression and regulation of angiotensin II receptor subtypes in rat fibroblasts and cardiomyocytic in culture
45. 2+ exchanger activity in the diabetic heart
46. Changes in protein kinase C in early cardiomyopathy and in the gracilis muscle in the BB/W or diabetic rat
47. Insulin-like growth factor 1 as a cardiac hormone: Physiological and pathophysiological implications in heart disease
48. 2+ through a wortmannin-sensitive pathway: Studies in rat and ferret isolated muscles
49. Insulin-like growth factors
50. Molecular analysis of insulin resistance in isolated ventricular myocytes of obese Zucker rats
51. +-channel expression of cultured neonatal rat ventricular myocytes
52. Left ventricular mass in diabetes-hypertension
53. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
54. Insulin resistance in microalbuminuric hypertension: Sites and mechanisms
55. The relationship of urinary albumin excretion rate to ambulatory blood pressure and erythrocyte sodium-lithium countertransport in NIDDM
56. Microalbuminuria in patients with non-insulin-dependent diabetes mellitus relates to noctumal systolic blood pressure
57. Diabetes and cardiovascular disease
58. The Canadian recommendations for the management of hypertension: On behalf of the task force for the development of the 1999 Canadian recommendations for the management of hypertension
59. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: A 7-year follow-up study
60. Aspirin therapy in diabetes